Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 1-Year Low – Should You Sell?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $26.88 and last traded at $27.34, with a volume of 34005 shares trading hands. The stock had previously closed at $27.33.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective for the company. Piper Sandler cut shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $66.00 to $36.00 in a research report on Tuesday, February 4th.

Amphastar Pharmaceuticals Trading Down 2.1 %

The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm has a market cap of $1.28 billion, a PE ratio of 8.94, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The company’s 50 day moving average price is $33.35 and its 200 day moving average price is $41.66.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rong Zhou sold 7,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the sale, the executive vice president now owns 118,469 shares of the company’s stock, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 27.10% of the company’s stock.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Several hedge funds have recently modified their holdings of AMPH. Smartleaf Asset Management LLC raised its position in Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after buying an additional 493 shares during the last quarter. Parkside Financial Bank & Trust raised its position in Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after acquiring an additional 871 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Amphastar Pharmaceuticals during the fourth quarter worth about $38,000. Tower Research Capital LLC TRC increased its holdings in Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock valued at $43,000 after buying an additional 348 shares in the last quarter. Finally, Huntington National Bank lifted its position in shares of Amphastar Pharmaceuticals by 36.9% during the 4th quarter. Huntington National Bank now owns 1,340 shares of the company’s stock valued at $50,000 after acquiring an additional 361 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.